Containing Discrete Coated Particles Pellets, Granules, Or Beads Patents (Class 424/458)
  • Patent number: 8663682
    Abstract: The present invention relates to a coated particle of active substance comprising a core, said core comprising the active substance and an acidic compound, said core being coated with a taste masking coating based on a polymer which is soluble at pH of 5 or less, and which is permeable at pH above 5.
    Type: Grant
    Filed: January 22, 2004
    Date of Patent: March 4, 2014
    Assignee: Ethypharm
    Inventors: Philippe Chenevier, Dominique Marechal
  • Patent number: 8663683
    Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: March 4, 2014
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
  • Publication number: 20140050784
    Abstract: The present invention relates to oral dosage forms comprising Memantine or a pharmaceutically acceptable salt thereof, pharmaceutical formulations comprising the oral dosage forms, and methods for treating mild, moderate or severe Alzheimer's dementia, or neuropathic pain comprising the oral dosage forms and formulations.
    Type: Application
    Filed: August 16, 2013
    Publication date: February 20, 2014
    Applicants: TEVA PHARMACEUTICALS USA, INC., TEVA PHARMACEUTICAL INDUSTRIES LTD.
    Inventors: Elena KAGAN, Nitzan SHAHAR, Elina HARONSKY, Gregg R. DEROSA
  • Patent number: 8652516
    Abstract: The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer; wherein the delayed release layer comprises about 4 to 6 mg of doxycycline monohydrate and a binding agent, and wherein the delayed release layer is coated with an enteric coating; wherein the enteric coating dissolves at pH of about 5 to 6, and wherein the enteric coating is coated with an immediate release layer; wherein the immediate release layer comprises about 32 mg of doxycycline monohydrate and a binding agent, wherein the relative mean Cmax of the pharmaceutical composition is within 80.00% to 125.00% of a Cmax value of 510±220.7 ng/mL, after administration of a single dose of the pharmaceutical composition to humans in a fasting state; and wherein the relative mean AUC(0-?) of the pharmaceutical composition is within 80.00% to 125.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: February 18, 2014
    Assignees: Cerovene, Inc., Galderma S.A.
    Inventors: Jean-Pierre Etchegaray, Nathalie Wagner, Manish S. Shah, Ray J. Difalco
  • Publication number: 20140044780
    Abstract: Described herein is a pharmaceutical composition comprising levetiracetam as an active ingredient to provide prolonged release characteristic to allow once a day dosage regime. The innovative formulation comprises levetiracetam and a hydrophobic polymer with or without additional release rate modifier(s). The formulation may comprise other pharmaceutically acceptable excipients. This invention also describes the processes of preparing such dosage forms.
    Type: Application
    Filed: August 5, 2013
    Publication date: February 13, 2014
    Inventors: I-Lan Tung Sue, Jung-Chung Lee
  • Publication number: 20140037723
    Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
    Type: Application
    Filed: October 8, 2013
    Publication date: February 6, 2014
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Patent number: 8642078
    Abstract: A sustained release pharmaceutical composition comprising coating comprising at least one water-insoluble permeable polymer and at least one water soluble polymer and homogenous cores containing only tolterodine or a salt thereof and microcrystalline cellulose is described.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: February 4, 2014
    Assignee: Lek Pharmaceuticals, D.D.
    Inventors: Igor Legen, Polonca Kuhar
  • Patent number: 8609136
    Abstract: Provided are methods, systems and apparatuses for producing delivery devices, for example, for oral intake of an agent. The method can include assembling one or more layers including one or more materials with an agent or an agent-releasing formulation to form an intergraded device; folding the intergrated delivery device to form a folded integrated delivery device; and at least partially enclosing the folded delivery device to a form suitable for oral delivery.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 17, 2013
    Assignee: Intec Pharma Ltd.
    Inventors: Moshe Tsabari, Avner Balshey, Erez Yofe, Michael Friedman
  • Patent number: 8591920
    Abstract: Emulsions of lipophiles such as glycerol monostearate which are compatible with acrylic copolymer emulsions are made stable by using an emulsion stabilizer such as polysorbate 80 in an amount by weight between 1% and 5% of the lipophile and homogenizing the emulsion wherein the emulsion micelles are less than 50 microns. The ability to make a stable emulsion of a lipophile is important in the coating process as it enables preparation and shipment of the lipophilic emulsion to the coater rather than the preparation of a lipophilic emulsion at the time of the coating process which involves a heating and cooling process.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: November 26, 2013
    Assignee: Emerson Resources, Inc.
    Inventor: Charles Signorino
  • Patent number: 8592364
    Abstract: Chemokines may be administered to a patient for immunotolerization. Chemokines include CCL19 and CCL21. Materials and methods for accomplishing tolerization and described.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: November 26, 2013
    Assignee: Ecole Polytechnique Federale de Lausanne (“EPFL”)
    Inventors: Melody A. Swartz, Jeffrey A. Hubbell, Alice A. Tomei, Jacqueline D. Shields, Iraklis Kourtis
  • Patent number: 8580301
    Abstract: The present invention is directed to a psychostimulant containing pharmaceutical composition comprising an enteric coating and showing a sustained release of said psychostimulant in vivo. The invention is further directed to the use of said pharmaceutical composition in the treatment of the Attention Deficit Hyperactivity Disorder (ADHD) and comorbidities, narcolepsy, fatigue and/or cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome or oncological diseases. Additionally, the present invention provides a method for the manufacture of said pharmaceutical composition.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: November 12, 2013
    Assignee: PEJO Iserlohn Heilmittel und Diaet GmbH & Co. KG
    Inventors: Reiner Poestges, Bernd Schneider, Richard Ammer
  • Patent number: 8580310
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: November 12, 2013
    Assignee: Purdue Pharma
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • Patent number: 8568774
    Abstract: A homogeneous gas-evolving composition is provided that includes an acid, a gas-evolving acid neutralizing agent, and at least one of an inorganic carbonate, inorganic bicarbonate, alkaline peroxide, or alkaline azide. A water-soluble desiccant is homogeneously intermixed with the acid and the gas-evolving acid neutralizing agent. The desiccant is present in an amount able to absorb ambient moisture equivalent to at least 0.01 total weight percent of the composition before gas evolution of more than 50% of the theoretical gas evolution available from the composition. To confer storage stability, the acid, the gas-evolving acid neutralizing agent, and water-soluble desiccant cumulatively have a water content of less than 1 total weight percent water. Through appropriate selection of a desiccant or inclusion of a surfactant foaming agent, the composition foams upon drenching with water. The composition is particularly well suited for consistent usage of glyphosate herbicide.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: October 29, 2013
    Assignee: The Andersons, Inc.
    Inventors: James R. Lynch, Timothy D. Birthisel, Jeffrey J. Fesko
  • Patent number: 8535799
    Abstract: A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low aqueous solubility and/or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5° C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and/or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: September 17, 2013
    Assignee: Veloxis Pharmaceuticals A/S
    Inventors: Anders Burr, Michiel Ringkjøbing-Elema, Jannie Egeskov Holm, Per Holm, Birgitte Møllgaard, Kirsten Schultz
  • Patent number: 8524829
    Abstract: The invention involves methods and products related to the micronization of hydrophobic drugs. A method of micronizing hydrophobic drugs using a set of solutions including an aqueous solution is provided. The invention also relates to products of micronized hydrophobic drugs and related methods of use.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: September 3, 2013
    Assignee: Brown University Research Foundation
    Inventors: Edith Mathiowitz, Christopher Thanos, Zhi Liu
  • Patent number: 8506981
    Abstract: The present invention is directed to implantable compositions comprising substantially spherical bioactive glass particles.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: August 13, 2013
    Assignee: Synergy Biomedical LLP
    Inventor: Mark D. Borden
  • Patent number: 8470364
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: June 25, 2013
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Patent number: 8465767
    Abstract: The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: June 18, 2013
    Assignee: Takeda GmbH
    Inventors: Rango Dietrich, Hartmut Ney
  • Patent number: 8460710
    Abstract: An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: September 14, 2004
    Date of Patent: June 11, 2013
    Assignee: Shionogi, Inc.
    Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
  • Patent number: 8449909
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: May 28, 2013
    Assignee: Collegium Pharmaceutical, Inc.
    Inventors: Jane Hirsh, Alison Fleming, Roman Rariy, Alexander Kilbanov
  • Publication number: 20130078304
    Abstract: The invention relates to a controlled-release formulation for preventing and/or treating sleep disorders comprising Zaleplon or a pharmaceutically acceptable salt thereof in immediate release form and Zolpidem or a pharmaceutically acceptable salt thereof in sustained release form, wherein Zaleplon or a pharmaceutically acceptable salt thereof and Zolpidem or a pharmaceutically acceptable salt thereof are released in two phases where the first phase is a immediate release phase of Zaleplon or a pharmaceutically acceptable salt thereof and the second phase is a sustained release phase of Zolpidem or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 28, 2011
    Publication date: March 28, 2013
    Applicant: TAIWAN BIOTECH CO., LTD.
    Inventors: HSIEN-JEN HSIEH, KUO-HUA YANG, CHIH-SHENG YANG, YU-CHENG WEI, CHUNG-HSUAN LU
  • Patent number: 8394406
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: March 12, 2013
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Patent number: 8394405
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: March 12, 2013
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Patent number: 8389004
    Abstract: The present invention relates to a process for producing protein microparticles in dilute organic acid solutions and in the absence of an alcohol such as ethanol. The microparticles are formed by dissolving a cereal prolamin protein in a concentrated organic acid solution with agitation and then diluting the solution with an aqueous solution. Protein microparticles having vacuoles are thus formed. The protein microparticles may be used to form powders, films, coatings, matrices, scaffolds and the like. Complete films can be formed from the protein microparticles of the invention.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: March 5, 2013
    Assignee: University of Pretoria
    Inventors: Janet Taylor, John Reginald Nuttall Taylor
  • Patent number: 8349353
    Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with cytotoxic agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: January 8, 2013
    Assignees: Otonomy, Inc., The Regents of the University of California
    Inventors: Jay Lichter, Andrew M. Trammel, Jeffrey P. Harris, Carl Lebel, Fabrice Piu, Qiang Ye, Luis A. Dellamary
  • Publication number: 20130004573
    Abstract: The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.
    Type: Application
    Filed: September 7, 2012
    Publication date: January 3, 2013
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Gurvinder Singh Rekhi, Richard Sidwell, Sharon Hamm
  • Publication number: 20120321708
    Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
    Type: Application
    Filed: August 27, 2012
    Publication date: December 20, 2012
    Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
  • Patent number: 8313775
    Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a sustained release dosage form, and a delayed release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: November 20, 2012
    Assignee: Shionogi Inc.
    Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
  • Patent number: 8313776
    Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a delayed release dosage form, and a sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: November 20, 2012
    Assignee: Shionogi Inc.
    Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
  • Publication number: 20120276017
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 3 to 8 hours, followed by an ascending release rate.
    Type: Application
    Filed: March 23, 2012
    Publication date: November 1, 2012
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 8298576
    Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: October 30, 2012
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
  • Patent number: 8268804
    Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: September 18, 2012
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
  • Patent number: 8252776
    Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: August 28, 2012
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
  • Patent number: 8246996
    Abstract: An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: August 20, 2004
    Date of Patent: August 21, 2012
    Assignee: Shionogi Inc.
    Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
  • Patent number: 8246986
    Abstract: Aqueous drug coatings including at least one insoluble drug, wherein the insoluble drug accounts for about 85 wt % to about 97 wt % of the drug coatings are described. Such drug coatings may include only one insoluble drug, two or more insoluble drugs, or one or more insoluble drugs in combination with one or more soluble drugs.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: August 21, 2012
    Assignee: Alza Corporation
    Inventors: Evangeline Cruz, Gregory Ruhlmann, Brenda Pollock, Sherry Li, Carmelita Garcia, Alfredo M. Wong, Ryan Bronz, Tracy Fink, David Edgren
  • Patent number: 8236345
    Abstract: A pharmaceutical composition, comprising a thiazolidinedione, such as Compound (I), metformin hydrochloride and a pharmaceutically acceptable carrier, wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: August 7, 2012
    Assignee: SmithKline Beecham Limited
    Inventors: Karen Lewis, Nicola Jayne Lilliott, Donald Colin MacKenzie
  • Patent number: 8226979
    Abstract: The present invention is directed to aqueous drug coatings that include at least one insoluble drug, wherein the drug accounts for about 85 wt % to about 97 wt % of the drug coatings. A drug coating according to the present invention may include only one insoluble drug, two or more insoluble drugs, or one or more insoluble drugs in combination with one or more soluble drugs. The present invention also includes drug coating formulations suitable for providing drug coatings according to the present invention and dosage forms that include a drug coating according to the present invention.
    Type: Grant
    Filed: April 11, 2011
    Date of Patent: July 24, 2012
    Assignee: Alza Corporation
    Inventors: Evangeline Cruz, Gregory Ruhlmann, Brenda Pollock, Sherry Li, Carmelita Garcia, Alfredo M. Wong, Ryan Bronz, Tracy Fink, David Edgren
  • Patent number: 8206740
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: June 26, 2012
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Patent number: 8197845
    Abstract: The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: June 12, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Mareke Hartig, Michael Trunk, Michael Walz
  • Patent number: 8197850
    Abstract: The invention concerns an oral galenic form for prolonged release of anti-hyperglycaemic (metformin) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 hours by overcoming the problems of bypass of the absorption window and the massive localised release of active principles. Therefor, said medicine comprises several thousand anti-hyperglycaemic (metformin) microcapsules each consisting of a core comprising at least an anti-hyperglycaemic agent and of a coating film applied on the core and enabling the prolonged release in vivo of the anti-hyperglycaemic agent. Said microcapsules have a grain size distribution ranging between 50 and 100 microns. The reproducibility of the transit kinetics and hence of bioavailability are very high. There results for the patient a lesser risk of hyperglycaemic or hypoglycaemic. The invention also concerns the preparation of said medicine and the use of a plurality of said microcapsules for making an anti-hyperglycaemic medicine.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: June 12, 2012
    Assignee: Flamel Technologies
    Inventors: Catherine Castan, Remi Meyrueix, Gerard Soula
  • Publication number: 20120128772
    Abstract: A controlled release pharmaceutical composition comprising Milnacipran or pharmaceutically acceptable salts thereof and hydrophobic release controlling agent. The composition releases 90% of the total amount of Milnacipran or pharmaceutically acceptable salts thereof between 8 to 20 hours when dissolution is carried out in 900 ml 0.1N HCl, USP apparatus Type I (Basket) at 100 rpm for 2 hrs, followed by 900 ml Phosphate buffer pH 6.8 USP apparatus Type I (Basket) at 100 rpm.
    Type: Application
    Filed: August 4, 2010
    Publication date: May 24, 2012
    Applicant: LUPIN LIMITED
    Inventors: Shirish Kumar Kulkarni, Rajesh Kulkani, Pandharinath Jadhav, Ashish Tiwari
  • Publication number: 20120128771
    Abstract: A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating. Each Timed Pulsatile Release (TPR) bead population exhibits pre-determined lag-time followed by differing release characteristics. The composition and thickness of the barrier coating, composition and thickness of the lag-time coating, ratio of IR beads to one or more TPR bead populations and total dose may be varied depending on the alkalinity, pH-dependent solubility and elimination half-life of the active ingredients to achieve target PK profiles (suitable for a once or twice daily dosing regimen) in patients in need of such medications.
    Type: Application
    Filed: July 19, 2011
    Publication date: May 24, 2012
    Inventor: Gopi M. Venkatesh
  • Publication number: 20120121702
    Abstract: A solid dosage form for oral administration comprising azithromycin in an amount below that which causes gastrointestinal side effects, which dosage form is a controlled release dosage form.
    Type: Application
    Filed: January 25, 2012
    Publication date: May 17, 2012
    Applicant: Dow Pharmaceutical Sciences, Inc.
    Inventors: Radhakrishnan Pillai, Pramod Sarpotdar, David W. Osborne, Gordon J. Dow
  • Patent number: 8153153
    Abstract: The invention discloses nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent, wherein equal moles of the positively charged chitosan and the negatively charged poly-glutamic acid substrate form an electrostatic network with zero surface charge enabling improved loading the bioactive agent.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: April 10, 2012
    Assignees: GP Medical, Inc., National Tsing Hua University
    Inventors: Hsing-Wen Sung, Kiran Sonaje, Hosheng Tu
  • Publication number: 20120058182
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Application
    Filed: April 9, 2010
    Publication date: March 8, 2012
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Patent number: 8124123
    Abstract: A solid dosage form for oral administration comprising azithromycin in an amount below that which causes gastrointestinal side effects, which dosage form is a controlled release dosage form.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: February 28, 2012
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Radhakrishnan Pillai, Pramod Sarpotdar, David W. Osborne, Gordon J. Dow
  • Publication number: 20120045508
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Application
    Filed: April 9, 2010
    Publication date: February 23, 2012
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Patent number: 8119163
    Abstract: The present invention provides a composition comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, for example, cefditoren pivoxil, useful in the treatment and prevention of infections and related conditions. The invention provides a composition which comprises nanoparticulate particles comprising the cefditoren, or a salt, derivative, prodrug, or other form thereof and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a cefditoren, or a salt, derivative, prodrug, or other form thereof, or nanoparticles comprising the same, in a pulsatile or continuous manner.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: February 21, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: John G Devane, Paul Stark, Niall M. N. Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
  • Patent number: 8114444
    Abstract: The present invention is providing a new sustained release drug preparation comprising such and inclusion complex of a medical compound with safe botanic drug (SBD), which sustains or retards the dissolution and release of the SBD at a controlled rate from the inclusion complex and hence from the drug preparation containing the SBD, so as to maintain the concentration of the SBD in blood at an effective level for prolonged time. SBD contains Kuguasu (KU) and saponins of Kugua (SAK). SBD is very safe and it is used for treating and preventing diabetes.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: February 14, 2012
    Inventor: Yaguang Liu
  • Publication number: 20110287096
    Abstract: Oral dosage forms for basic amine drugs, the dosage forms having a gastro-retentive component and a non gastro-retentive component. These dosage forms are capable of providing both IR and SR release rates for these drugs. In addition, they provide for release of the drug in the stomach and/or intestine of a mammal to which such dosage forms are administered. Such dosage forms include tablets and capsules. Such dosage forms provide improved bioavailability of otherwise poorly bioavailable basic amine drugs.
    Type: Application
    Filed: May 18, 2011
    Publication date: November 24, 2011
    Applicant: ABON PHARMACEUTICALS, LLC
    Inventors: Sudhir GORUKANTI, Yanming Zu, Phanidhara Kotamraj, Karunakar Neelam, Salah U. Ahmed